Spectrum stockholders will receive up front of 0.1783 ASRT shares per SPPI share ($1.14/share) representing a premium of 65% plus one CVR per Spectrum share for total consideration of ~$1.34/share & an additional $0.20/share (~$43M) in cash or stock at Assertio’s election for $1.34 ($291M) representing a premium of 94% to Spectrum’s latest closing price. The acquisition is expected to close in Q3’23
Assertio stockholders to own ~65% & Spectrum stockholders will own ~ 35% of combined company. Spectrum’s combined assets & commercial infrastructure will accelerate Rolvedon’s launch for patients’ benefit & drive further growth
The combination of Assertio’s Omni-Channel digital sales capabilities & Rolvedon’s in-person commercial team will enhance market access & growth across all products
Ref: Globenewswire | Image: Assertio
Related News:- Collegium to Acquire US Rights of Assertio’s Nucynta Franchise for $375M
